BOT.AXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 15:10):

Stats
本日の出来高	3.27M
平均出来高	2.57M
時価総額	346.53M
EPS	$0 ( 2024-02-25 )
次の収益日	( $0 ) 2024-07-28
Last Dividend	$95.85 ( 1996-10-03 )
Next Dividend	$0 ( N/A )
P/E	-22.00
ATR14	$0.00200 (0.93%)

ボリューム相関

長: 0.12 (neutral)

短: 0.22 (neutral)

Signal:(40.465) Neutral

Botanix Pharmaceuticals 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Botanix Pharmaceuticals 相関 - 通貨/商品

0.00
( neutral )

-0.44
( neutral )

Botanix Pharmaceuticals 財務諸表

Annual	2023
収益:	$914 973
総利益:	$-3.05M (-332.90 %)
EPS:	$-0.00790

FY	2023
収益:	$914 973
総利益:	$-3.05M (-332.90 %)
EPS:	$-0.00790

FY	2022
収益:	$2.75M
総利益:	$2.61M (94.79 %)
EPS:	$-0.0135

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00438

Financial Reports:

No articles found.

Botanix Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Botanix Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$81.28	1994-02-18
Last Dividend	$95.85	1996-10-03
Next Dividend	$0	N/A
Payout Date	1996-10-25
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$510.23	--
Avg. Dividend % Per Year	0.00%	--
Score	1.06	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-11-04)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.06

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
VEA.AX	Ex Dividend Junior	2023-09-05	Semi-Annually	0.00%
DTL.AX	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%
OPH.AX	No Dividend Player	2023-06-30	Annually	0.00%
AGL.AX	Ex Dividend Knight	2023-08-23	Semi-Annually	0.00%
GEM.AX	Ex Dividend Junior	2023-09-07	Annually	0.00%
QRI.AX	Ex Dividend Junior	2023-09-05	Monthly	0.00%
BFG.AX	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%
JLG.AX	Ex Dividend Junior	2023-09-01	Annually	0.00%
SKC.AX	Ex Dividend Junior	2023-09-07	Annually	0.00%
CKF.AX	Ex Dividend Knight	2023-07-10	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-11.08	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.210	1.200	-7.01	-8.41	[0 - 0.3]
returnOnEquityTTM	-0.293	1.500	-4.37	-6.56	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.50	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	8.09	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.99	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-858.83	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.00702	2.00	-0.00234	-0.00468	[0 - 30]
freeCashFlowPerShareTTM	-0.0186	2.00	-0.00932	-0.0186	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-5.76	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-11.10	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0190	0.800	-3.21	-2.57	[0.5 - 2]
Total Score				-3.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-31.58	1.000	-3.29	0	[1 - 100]
returnOnEquityTTM	-0.293	2.50	-2.81	-6.56	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0186	2.00	-0.00621	-0.0186	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00702	2.00	-0.00234	-0.00468	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.106	1.500	-2.62	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-11.17	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.43

Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.